Switch theme
Sign up to access all valuation multiples
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
2012
683
LTM Revenue $499M
LTM EBITDA -$175M
$5.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Axsome Therapeutics has a last 12-month revenue (LTM) of $499M and a last 12-month EBITDA of -$175M.
In the most recent fiscal year, Axsome Therapeutics achieved revenue of $386M and an EBITDA of -$273M.
Axsome Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Axsome Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $499M | XXX | $386M | XXX | XXX | XXX |
| Gross Profit | $456M | XXX | $352M | XXX | XXX | XXX |
| Gross Margin | 91% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | -$175M | XXX | -$273M | XXX | XXX | XXX |
| EBITDA Margin | -35% | XXX | -71% | XXX | XXX | XXX |
| EBIT | -$223M | XXX | -$252M | XXX | XXX | XXX |
| EBIT Margin | -45% | XXX | -65% | XXX | XXX | XXX |
| Net Profit | -$231M | XXX | -$287M | XXX | XXX | XXX |
| Net Margin | -46% | XXX | -74% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Axsome Therapeutics's stock price is $103.
Axsome Therapeutics has current market cap of $5.1B, and EV of $5.0B.
See Axsome Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.0B | $5.1B | XXX | XXX | XXX | XXX | $-4.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Axsome Therapeutics has market cap of $5.1B and EV of $5.0B.
Axsome Therapeutics's trades at 12.9x EV/Revenue multiple, and -18.3x EV/EBITDA.
Equity research analysts estimate Axsome Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Axsome Therapeutics has a P/E ratio of -21.9x.
See valuation multiples for Axsome Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.1B | XXX | $5.1B | XXX | XXX | XXX |
| EV (current) | $5.0B | XXX | $5.0B | XXX | XXX | XXX |
| EV/Revenue | 10.0x | XXX | 12.9x | XXX | XXX | XXX |
| EV/EBITDA | -28.5x | XXX | -18.3x | XXX | XXX | XXX |
| EV/EBIT | -22.3x | XXX | -19.7x | XXX | XXX | XXX |
| EV/Gross Profit | 10.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -21.9x | XXX | -17.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -38.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAxsome Therapeutics's last 12 month revenue growth is 59%
Axsome Therapeutics's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.9M for the same period.
Axsome Therapeutics's rule of 40 is -24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Axsome Therapeutics's rule of X is 113% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Axsome Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 59% | XXX | 59% | XXX | XXX | XXX |
| EBITDA Margin | -35% | XXX | -71% | XXX | XXX | XXX |
| EBITDA Growth | -116% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -24% | XXX | -12% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 113% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 157% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Axsome Therapeutics acquired XXX companies to date.
Last acquisition by Axsome Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Axsome Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Axsome Therapeutics founded? | Axsome Therapeutics was founded in 2012. |
| Where is Axsome Therapeutics headquartered? | Axsome Therapeutics is headquartered in United States of America. |
| How many employees does Axsome Therapeutics have? | As of today, Axsome Therapeutics has 683 employees. |
| Who is the CEO of Axsome Therapeutics? | Axsome Therapeutics's CEO is Dr. Herriot Tabuteau, M.D.. |
| Is Axsome Therapeutics publicy listed? | Yes, Axsome Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Axsome Therapeutics? | Axsome Therapeutics trades under AXSM ticker. |
| When did Axsome Therapeutics go public? | Axsome Therapeutics went public in 2015. |
| Who are competitors of Axsome Therapeutics? | Similar companies to Axsome Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Axsome Therapeutics? | Axsome Therapeutics's current market cap is $5.1B |
| What is the current revenue of Axsome Therapeutics? | Axsome Therapeutics's last 12 months revenue is $499M. |
| What is the current revenue growth of Axsome Therapeutics? | Axsome Therapeutics revenue growth (NTM/LTM) is 59%. |
| What is the current EV/Revenue multiple of Axsome Therapeutics? | Current revenue multiple of Axsome Therapeutics is 10.0x. |
| Is Axsome Therapeutics profitable? | Yes, Axsome Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Axsome Therapeutics? | Axsome Therapeutics's last 12 months EBITDA is -$175M. |
| What is Axsome Therapeutics's EBITDA margin? | Axsome Therapeutics's last 12 months EBITDA margin is -35%. |
| What is the current EV/EBITDA multiple of Axsome Therapeutics? | Current EBITDA multiple of Axsome Therapeutics is -28.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
